오령산의 피오글리타존 부작용 경감 효과 = Oryung-san Ameliorates Pioglitazone Side Effects

다국어 초록 (Multilingual Abstract)

Thiazolidinediones (TZDs) induce insulin sensitization through the activation of PPAR${\gamma}$. However, the undesirable effect such as weight gain was observed. The purpose of this study was to find out an herbal drug that could reduce the side effects of pioglitazone. Among herbal formula that we have searched, oryung-san (OR) inhibited the differentiation of preadipocytes and did not affect on glucose uptake in 3T3-L1 adipocytes. In vitro, glucose uptake assay and Oil Red-O staining in 3T3-L1 adipocytes were conducted. In vivo, pioglitazone (PIO, 30 mg/kg), oryung-san (OR, 300 mg/kg), or pioglitazone co-administered with oryung-san (PIO+OR) were administered orally for 7 weeks in high fat diet (HFD) fed ICR mice and measured the body weight and blood glucose level every week. PIO+OR group significantly reduced body weight gain, triglyceride, and total cholesterol compared to PIO group. In addition, PIO+OR group showed a significant reduction of plasma glucose level (72%) compared to HFD control group. Insulin levels in PIO+OR group was also markedly decreased by 85% and 41% compared to HFD control and PIO group, respectively. Diameter of white adipocytes was decreased in the PIO+OR group compared to that in PIO group. Moreover, PIO+OR group reduced expression of PPAR${\gamma}$ and SREBP1a compared to PIO group. Taken together, oryung-san can improve side effects of pioglitazone, such as weight gain and edema, and shows a synergistic effect in plasma insulin levels.

참고문헌 (Reference)

1 "adipose-predominant exression and induction early in adipocyte differentiation. Endocrinology 135" 1994

2 "Thiazolidinedions: a comparative review of approved uses" 2 : 429-, 2000

3 "Therapeutic roles of peroxisome proliferator-activated receptor agonists" 54 : 2460-, 2005

4 "The nuclear hormone receptor gene superfamily" 46 : 443-, 1995

5 "Stimulation of adipogenesis in fibroblasts by PPAR g2" tonto (tonto): 1994

6 P, "Single-step method of RNA isolation by acid guanidium thiocyanate-phenol chloroform extraction. Anal. Biochem. 162" 1987

7 "Peroxisome proliferator-actovated receptor gene expression in human tissues" 99 : 2416-, 1997

8 "PPARs: therapeutic targets for metabolic disease" 26 : 244-, 2005

9 "PPAR-gand the control of adipogenesis" 79 : 111-, 1997

10 Misra P, "PAT5A: a partial agonist of peroxisome proliferator-activated receptor g is a potent antidiabetic thiazolidinedione yet weakly adipogenic." 306 : 763-, 2003

11 "New approaches in the treatment of type 2 diabetes." 4 : 461-, 2000

12 "Insulin resistance and antidiabetic drugs" 58 : 1511-, 1999

13 Berger J. P, "Distinct properties and advantages of a novel peroxisome proliferator-activated protein [g] selective modulator" 17 : 662-, 2003

14 "Dfferentiating members of th thiazoli- dinedione class: a focus on safety" 18 : 23-, 2002

15 "Definition, diagnosis and classification of diabetes mellitus and its complications" 13 : 539-, 1998

16 Huang C, "Berberine inhibits 3T3-L1 adipocyte differentiation through the PPAR-g pathway" 348 : 571-, 2006

17 Chakrabrti R, "Antidiabetic and hypolipidemic potential of DRF 2519-a dual activator of PPAR-a and PPAR-g." 491 : 195-, 2004

18 Rocchi S, "A unique PPAR-g ligand with potent insulin-sensitizing yet weak adipogenic activity" 8 : 737-, 2001

19 Oberfield J. L, "A peroxisome proliferator-activated receptor ligand inhibits adipocyte differentiation" 96 : 6102-, 1999